Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EloraTZP in Adults With Obesity Without Type 2 Diabetes
NCT07881432Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2026
- Primary completion
- Oct 2029
- Countries
- 9
01
Overview
Phase 3, randomised trial of eloralintide + tirzepatide in obesity (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 100 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
eloralintide + tirzepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07881432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881432.